# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k063232   
B. Purpose for Submission: New device for intact parathyroid hormone (PTH), calibrator and control materials   
C. Measurand: PTH   
D. Type of Test: Quantitative chemiluminescent microparticle immunoassay   
E. Applicant: BIOKIT S.A.   
F. Proprietary and Established Names: ARCHITECT Intact PTH reagents, calibrators (A-F) and controls (Low, Medium, High), models 8K25-20, 8K25-25, 8K25-01

# G. Regulatory Information:

1. Regulation section: 21CFR Sec. 862.1545-Parathyroid hormone test system 21CFR Sec. 862.1150 Calibrator 21CFR Sec. 862.1660 Quality control material (assayed and unassayed)

2. Classification: Class 2, 2, 1 (reserved), respectively

3. Product code: CEW - radioimmunoassay, parathyroid hormone JIT - calibrator, secondary JJX - single (specified) analyte controls (assayed and unassayed)

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indication(s) for use below

2. Indication(s) for use:

Reagents The ARCHITECT Intact PTH assay is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of intact parathyroid hormone (PTH) in human serum and plasma on the ARCHITECT i System. The ARCHITECT Intact PTH assay is intended to be used as an aid in the differential diagnosis of hpyercalcemia, hypocalcemia and parathyroid disorders.

Calibrators   
The ARCHITECT Intact PTH Calibrators are for the calibration of the ARCHITECT i System when used for the quantitative determination of intact PTH in human serum and plasma. Controls   
The ARCHITECT Intact PTH Controls are for the use in quality control to monitor the accuracy and precision of the ARCHITECT Intact PTH assay on the ARCHITECT i System for human serum and plasma.

For in vitro diagnostic use

3. Special conditions for use statement(s): Prescription use only The ARCHITECT Intact PTH assay has not been clinically validated for intra-operative use.

4. Special instrument requirements: ARCHITECT i System

# I. Device Description:

CHITECT Intact PTH Reagent Kit

• MICROPARTICLES 1 or 4 Bottle(s) (6.6 mL each) Anti-PTH (goat, polyclonal) coated microparticles in TRIS buffer Preservative: sodium azide   
• CONJUGATE 1 or 4 Bottle(s) ( $5 . 9 \mathrm { m L }$ each) Anti -PTH (goat, polyclonal) acridinium -labeled conjugate in MES buffer with protein (bovine, goat) stabilizer. Preservative: sodium azide ASSAY DILUENT 1 or 4 Bottle(s) ( $1 0 . 0 \mathrm { m L }$ each) Intact PTH Assay Diluent containing phosphate buffer with protein (bovine, goat) stabilizer Preservative: sodium azide

ARCHITECT $\textsuperscript { \textregistered }$ Intact PTH Calibrators contents: 6 bottles $4 . 0 \mathrm { m L }$ each) of ARCHITECT Intact PTH Calibrators Calibrator A contains Bis Tris Propane buffer with protein (bovine) stabilizer Calibrators B-F contain PTH (synthetic peptide) in Bis Tris Propane buffer with protein (bovine) stabilizer. Preservatives: sodium azide and ProClin $^ \mathrm { \textregistered }$ 300

The calibrators yield the following concentrations: Calibrator Target concentrat

A. B. C.   
D.   
E.   
F.

ARCHITECT $^ \mathrm { \textregistered }$ Intact PTH control contents:

$3 \times 1$ Bottle $\mathrm { 8 . 0 \ m L }$ each) of ARCHITECT Intact PTH controls contain PTH (synthetic peptide) in Bis Tris Propane buffer with protein (bovine) stabilizer. Preservatives: sodium azide and ProClin $^ \mathrm { \textregistered }$ 300.

The following concentration ranges may be used for individual replicate control specifications on the ARCHITECT i System when used with the Routine protocol:

<table><tr><td>Control</td><td>Target Concentration</td><td>Range</td></tr><tr><td>Low</td><td>(pg/mL) 10.0</td><td>(pg/mL) 6.0 - 14.0</td></tr><tr><td>Med</td><td>65.0</td><td>42.3  87.8</td></tr><tr><td>High</td><td>250.0</td><td>162.5  337.5</td></tr></table>

The following concentration ranges may be used for individual replicate control specifications on the ARCHITECT i System when used with the STAT protocol:

<table><tr><td>Control</td><td>Target Concentration</td><td>Range</td></tr><tr><td>Low</td><td>(pg/mL) 8.3</td><td>(pg/mL) 5.0 - 11.7</td></tr><tr><td>Med</td><td>54.2</td><td>35.2 - 73.1</td></tr><tr><td>High</td><td>208.3</td><td>135.4 - 281.2</td></tr></table>

Although control materials produced different target values and ranges, human serum and plasma specimens tested with the STAT or Routine protocol will produce equivalent results. The different ranges for the Controls in the STAT and Routine protocol are associated with the matrix used for the Intact PTH Controls.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Roche Elecsys Parathyroid Hormone Test System

2. Predicate 510(k) number(s): k992680

3. Comparison with predicate:

Similarities:   

<table><tr><td rowspan=1 colspan=1>CHARACTERISTICS</td><td rowspan=1 colspan=2>DEVICE</td><td rowspan=1 colspan=1>PREDICATE</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>STAT</td><td rowspan=1 colspan=1>ROUTINE</td><td rowspan=1 colspan=1>Intact PTH</td></tr><tr><td rowspan=1 colspan=1>Product Type</td><td rowspan=1 colspan=1>Immunoassay</td><td rowspan=1 colspan=1>Immunoassay</td><td rowspan=1 colspan=1>Immunoassay</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>ChemiluminescentMicroparticleImmunoassay(CMIA)</td><td rowspan=1 colspan=1>ChemiluminescentMicroparticleImmunoassay(CMIA)</td><td rowspan=1 colspan=1>ElectrochemiluminescenceImmunoassay (ECLIA)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>TheARCHITECTIntact PTH assay isan in vitrochemiluminescentmicroparticleimmunoassay(CMIA) for thequantitativedetermination ofintact parathyroidhormone (PTH) inhuman serum andplasma on theARCHITECT iSystem.</td><td rowspan=1 colspan=1>The ARCHITECT®Intact PTH assay is an invitro chemiluminescentmicroparticleimmunoassay (CMIA) forthe quantitativedetermination of intactparathyroid hormone(PTH) in human serumand plasma on theARCHITECT i System.</td><td rowspan=1 colspan=1>The Roche ElecsysImmunoassay for the invitro quantitativedetermination of intactparathyroid hormone inhuman serum and plasmafor the differentialdiagnosis ofhypercalcemia andhypocalcemia. TheElectrochemiluminescenceImmunoassay (ECLIA) isintended for use on theRoche Elecsys 1010/2010and modular analyticasE170 (Elecsys module)immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Direct sandwichimmunoassay</td><td rowspan=1 colspan=1>Direct sandwichimmunoassay</td><td rowspan=1 colspan=1>Sandwich principle</td></tr><tr><td rowspan=1 colspan=1>Interpretation of Results</td><td rowspan=1 colspan=1>Standard Curve</td><td rowspan=1 colspan=1>Standard Curve</td><td rowspan=1 colspan=1>Standard Curve</td></tr></table>

Differences:   

<table><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">STAT</td><td colspan="1" rowspan="1">ROUTINE</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Components</td><td colspan="1" rowspan="1">Microparticles - 1or 4Bottle(s) (6.6 mL each) Anti-PTH (goat, polyclonal)coated microparticles inTRIS buffer. Preservative:sodium azideConjugate -1or 4 Bottle(s)(5.9 mL each) Anti-iPTH(goat, polyclonal)acridinium-labeled conjugatein MES buffer with protein</td><td colspan="1" rowspan="1">Microparticles - 1or 4Bottle(s) (6.6 mL each)Anti-PTH (goat, polyclonal)coated microparticles inTRIS buffer. Preservative:sodium azideConjugate - 1or 4 Bottle(s)(5.9 mL each) Anti-iPTH(goat, polyclonal)acridinium-labeledconjugate in MES buffer</td><td colspan="1" rowspan="1">Microparticles - 1 bottle6.5mL: Streptavidin-coatedmicroparticles, 0.72 mg/mL;binding capacity: 470 ngbiotin/mg microparticles;preservativeR1 - Anti -PTH-Ab~biotin-1 bottle (10.0 mL)Biotinylated monoclonalanti-PTH antibody (mouse)2.3 mg/L; phosphate buffer</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(bovine, goat) stabilizer.Preservative: sodium azide.Assay Diluent - 1or 4Bottle(s) (10.0 mL each)Intact PTH Assay Diluentcontaining phosphate bufferWith protein (bovine, goat)stabilizer. Preservative:sodium azide.</td><td colspan="1" rowspan="1">with protein (bovine, goat)stabilizer. Preservative:sodium azide.Assay Diluent - 1or 4Bottle(s) (10.0 mL each)Intact PTH Assay Diluentcontaining phosphate bufferwith protein (bovine, goat)stabilizer. Preservative:sodium azide.</td><td colspan="1" rowspan="1">100 mmol/L, pH 7.0;preservative.R2 - Anti -PTH-Ab~Ru1 bottle, 10 mL:Monoclonal anti-PTHantibody (mouse) labeledwith ruthenium complex 2.0mg/L; phosphate buffer100mmol/L, pH 7.0;preservative</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">K+ EDTA, Na Heparin, LiHeparin and Serum</td><td colspan="1" rowspan="1">K+ EDTA, Na Heparin, LiHeparin and Serum</td><td colspan="1" rowspan="1">K+ EDTA plasma, Serum</td></tr><tr><td colspan="1" rowspan="1">Incubation time</td><td colspan="1" rowspan="1">STAT mode the firstincubation is 4 minutes(18 minutes to first result)</td><td colspan="1" rowspan="1">Routine mode the firstincubation is 18 minutes(29 minutes to first result)</td><td colspan="1" rowspan="1">18 minutes to first result(Elecsys 2010)9 minutes to first result(Elecsys 1010)</td></tr></table>

Calibrators:

Similarities:   

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The ARCHITECT® PTHCalibrators are for the calibrationof the ARCHITECT i Systemwhen used for the quantitativedetermination of Intact PTH inhuman serum and plasma.</td><td rowspan=1 colspan=1>Elecsys® PTH CalSet is used forcalibrating the PTH assay on theElecsys immunoassay systems.</td></tr><tr><td rowspan=1 colspan=1>Standardization/Traceability</td><td rowspan=1 colspan=1>Against a commercial PTH testand anchored to the WHOStandard Material NIBSC CODE:79/500.</td><td rowspan=1 colspan=1>Against a commercial PTH test(RIA)</td></tr></table>

Differences:   

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Calibrator Components</td><td rowspan=1 colspan=1>Synthetic peptide PTH in a BisTris Propane buffer</td><td rowspan=1 colspan=1>Synthetic peptide in a humanserum matrix</td></tr><tr><td rowspan=1 colspan=1>Calibrator Concentrations</td><td rowspan=1 colspan=1>6 levels</td><td rowspan=1 colspan=1>2 levels</td></tr></table>

Controls: Similarities:   

<table><tr><td>Characteristics</td><td>Device</td><td>Predicate</td></tr><tr><td>Intended Use</td><td>The ARCHITECT® Intact PTH Controls are for the use in quality control to monitor the accuracy and precision of the ARCHITECT Intact PTH assay on the ARCHITECT i System for human serum and plasma.</td><td>Elecsys® PreciControl Bone is used for the quality control of PTH on Elecsys immunoassay systems.</td></tr><tr><td>Control Concentrations</td><td>3 levels</td><td>3 levels</td></tr></table>

Differences:

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Control Components</td><td rowspan=1 colspan=1>PTH synthetic peptide in Bis TrisPropane buffer</td><td rowspan=1 colspan=1>Lyophilized control serum basedequine serum</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI - Interference Testing in Clinical Chemistry - EP07-A2   
CLSI - Evaluation of Precision Performance of Clinical Chemistry Devices - EP05-A2   
FDA - Points to Consider Guidance Document on Assayed and Unassayed Quality   
Control Material; Draft

# L. Test Principle:

The ARCHITECT Intact PTH assay is a two-step sandwich immunoassay for the quantitative determination of intact PTH in human serum and plasma using chemiluminescent microparticle immunoassay (CMIA) technology.

In the first step, sample, assay diluent, and anti -PTH coated paramagnetic microparticles are combined. Intact PTH present in the sample binds to the anti-PTH coated microparticles. After washing, anti-PTH acridinium-labeled conjugate is added to create a reaction mixture in the second step. Following another wash cycle, pretrigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs).

The ARCHITECT Intact PTH can be used with both STAT and Routine Protocols. The STAT protocol has a shorter incubation time in comparison to the Routine protocol. Routine and STAT protocols require separate calibrations due to different incubation time but require only one reagent kit.

A direct relationship exists between the amount of intact PTH in the sample and the RLUs detected by the ARCHITECT i System optics.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

A study was performed for the ARCHITECT Intact PTH assay, based on guidance from the Clinical Laboratory Standards Institute (CLSI) Protocol EP5-A. Multiple ARCHITECT Intact PTH control lots were assayed using two lots of reagents in replicates of two at two separate times per day for 20 days at one site on two instruments using the STAT protocol and at a second site on two instruments using the Routine protocol.

In addition, a second precision study was performed, where two lots of reagents were assayed in four replicates per run at two separate times per day over 10 days on one instrument at a third site using the STAT protocol and on one instrument at a fourth site using the Routine protocol. Each reagent lot used a single calibration curve throughout the study. Data from both studies are summarized in the following tables.

ARCHITECT Intact PTH Precision Using STAT Protocol   

<table><tr><td colspan="3">Mean</td><td colspan="3">Within Run</td></tr><tr><td>Sample Low</td><td>n</td><td>Conc. (pg/mL)</td><td>SD</td><td>%CV</td><td>SD %CV</td></tr><tr><td>Control Medium</td><td>878</td><td>8.5</td><td>0.74</td><td>8.7 0.74</td><td>8.7</td></tr><tr><td>Control High</td><td>880</td><td>56.5</td><td>2.34</td><td>4.1 2.35</td><td>4.2</td></tr><tr><td>Control</td><td>880</td><td>208.9</td><td>8.62</td><td>4.1 8.62</td><td>4.1</td></tr><tr><td colspan="6">ARCHITECT Intact PTH Precision Using Routine Protocol</td></tr><tr><td>Sample</td><td>n</td><td>Mean Conc. (pg/mL)</td><td>Within Run SD</td><td>%CV SD</td><td>Total %CV</td></tr><tr><td>Low Control Medium</td><td>880</td><td>10.7</td><td>0.65</td><td>6.1 0.69</td><td>6.4</td></tr><tr><td>Control</td><td>880</td><td>69.6</td><td>2.28</td><td>3.3 2.31</td><td>3.3</td></tr><tr><td>High Control</td><td>880</td><td>255.8</td><td>7.40</td><td>2.9 7.56</td><td>3.0</td></tr></table>

A third study was performed with high concentrated samples with one lot of reagents in replicates of two at two separate times per day for 20 days at one site on one instrument using the STAT protocol and the Routine protocol. Each reagent lot used a single calibration curve throughout the study. Data from both studies are summarized in the following tables.

<table><tr><td colspan="7"></td></tr><tr><td colspan="3">ARCHITECT Intact PTH Precision Using STAT Protocol Mean Conc.</td><td colspan="2">Within Run</td><td colspan="2">Total</td></tr><tr><td>Sample</td><td></td><td></td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>High Concentration</td><td>n 80</td><td>(pg/mL) 828.6</td><td>25.9</td><td>3.2</td><td>31.8</td><td>4.0</td></tr><tr><td>High Concentration</td><td>80</td><td>2039.9</td><td>49.5</td><td>2.5</td><td>67.4</td><td>3.4</td></tr><tr><td colspan="3"></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">ARCHITECT Intact PTH Precision Using Routine Protocol</td></tr><tr><td></td><td></td><td>Mean Conc.</td><td>Within Run</td><td></td><td>Total</td><td></td></tr><tr><td>Sample</td><td>n</td><td>(pg/mL)</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td>High Concentration</td><td>80</td><td>988.7</td><td>36.8</td><td>4.6</td><td>41.7</td><td>5.2</td></tr><tr><td>High Concentration</td><td>80</td><td>2392.4</td><td>78.5</td><td>3.9</td><td>88.8</td><td>4.4</td></tr></table>

$b$ . Linearity/assay reportable range: MEASUREMENT RANGE The measurement for the ARCHITECT Intact PTH assay is STAT: $4 . 0 \ : \mathrm { p g / m L }$ to $2 2 2 7 \ : \mathrm { p g / m L }$ Routine: $3 . 0 \ : \mathrm { p g / m L }$ to $2 2 5 7 \mathrm { p g / m L }$

The range of measurement was established with dilution recovery studies and detection limit (functional sensitivity) below.

The high and low calibrators have been diluted to yield the below expected values dilutions. The obtained dilutions have been measured with the ARCHITECT Instrument using both STAT and Routine protocols. The percent recovery has been calculated.

<table><tr><td rowspan="2"></td><td rowspan="2">Routine expected observed</td><td colspan="2"></td></tr><tr><td>% recovery</td><td>% CV</td></tr><tr><td>dil 1</td><td>3000 2994</td><td>99.8</td><td>0.1</td></tr><tr><td>dil 2</td><td>1502.4 1551</td><td>103.3</td><td>0.5</td></tr><tr><td>dil 3</td><td>2251.2 2312</td><td>102.7</td><td>0.1</td></tr><tr><td>dil 4</td><td>1876.8 1841</td><td>98.1</td><td>6.2</td></tr><tr><td>dil 5</td><td>1689.6 1680</td><td>99.5</td><td>0.2</td></tr><tr><td>dil 6</td><td>1596.1 1647</td><td>103 .2</td><td>1.4</td></tr><tr><td>dil 7</td><td>753.6 762</td><td>101.2</td><td>0.2</td></tr><tr><td>dil 8</td><td>379.2 362</td><td>95.6</td><td>3.8</td></tr><tr><td>dil 9</td><td>192 181</td><td>94 .4</td><td>1.1</td></tr><tr><td>dil 10</td><td>98.4 92</td><td>93.6</td><td>0.5</td></tr><tr><td>dil 11</td><td>4.8 5</td><td>109 .4</td><td>6.7</td></tr><tr><td></td><td rowspan="2">STAT expected</td><td colspan="2"></td></tr><tr><td>observed</td><td>% % CV recovery</td></tr><tr><td>dil 1</td><td>2500 2480</td><td>99 .2</td><td>2.1</td></tr><tr><td>dil 2</td><td>1252 1263</td><td>100.8</td><td>0.4</td></tr><tr><td>dil 3</td><td>1876 1796</td><td>95.7</td><td>1.2</td></tr><tr><td>dil 4</td><td>1564 1447</td><td>92.5</td><td>0.1</td></tr><tr><td>dil 5</td><td>1408 1349</td><td>95.8</td><td>0.5</td></tr><tr><td>dil 6</td><td>1330 1285</td><td>96.6</td><td>1.6</td></tr><tr><td>dil 7</td><td>628 584</td><td>93.0</td><td>15.8</td></tr><tr><td>dil 8</td><td>316 306</td><td>97.0</td><td>4.3</td></tr><tr><td>dil 9</td><td>160 154</td><td>96.1</td><td>0.6</td></tr><tr><td>dil 10</td><td>82 76</td><td>93.2</td><td>1.2</td></tr><tr><td>dil 11</td><td>4 4</td><td>98.8</td><td>1.8</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Calibrators and controls are manufactured using Human Parathyroid Hormone and are traceable to WHO International reference preparation of Parathyroid Hormone, Human, for Immunoassay code: 79/500.

Value assignments and verification processes for ARCHITECT Intact PTH calibrators and controls are done using an internal protocol.

A study was conducted to determine the shelf-life integrity of the ARCHITECT Intact PTH Reagent Kit, Calibrator, and Controls when stored at the recommended storage condition of 2 to $8 \mathrm { { } ^ { \circ } C }$ .

A real-time stability study supports a shelf life of 13 months for the ARCHITECT Intact PTH Reagent, Calibrator, and Control kit at the recommended storage condition of 2 to $8 \mathrm { { } ^ { \circ } C }$ . The expiration date of 12 months is being assigned for the ARCHITECT Intact PTH Reagent, Calibrator and Control kit.

# d. Detection limit:

A study was performed using human samples with concentrations targeted at $3 \ : \mathrm { p g / m L }$ , $4 \ : \mathrm { p g / m L }$ and $5 \ : \mathrm { p g / m L }$ of intact PTH. Those samples were tested in replicates of two over 10 days using two reagent lots on two instruments using the STAT protocol and on one instrument using the Routine protocol.

Functional sensitivity (lowest concretion with a $C V \leq 2 0 \%$ ) was determined to $\mathbf { \delta b e } = 3 ~ \mathbf { p g } / \mathbf { m L }$ for the Routine protocol and $\mathbf { \Sigma } = 4 ~ \mathrm { p g / m L }$ for the STAT protocol.

e. Analytical specificity:

# Specificity

The specificity of the ARCHITECT Intact PTH assay is designed to have a cross-reactivity $= 0 . 0 1 \%$ when tested with structurally similar compounds listed in the table below. A study was performed with the ARCHITECT Intact PTH assay based on guidance from the for Clinical Laboratory Standards Institute (CLSI) Protocol EP7-A. Aliquots of ARCHITECT Intact PTH Calibrator A were supplemented with potential cross-reactants at the concentrations listed and tested for intact PTH. Data from this study are summarized in the following table.

<table><tr><td>PTH fragment</td><td>Concentrations</td><td>% Cross-Reactivity</td></tr><tr><td>1-34</td><td>100000 pg/mL</td><td>0.00</td></tr><tr><td>39-68</td><td>100000 pg/mL</td><td>0.00</td></tr><tr><td>53-84</td><td>100000 pg/mL</td><td>0.00</td></tr><tr><td>44-68</td><td>100000 pg/mL</td><td>0.00</td></tr><tr><td>39-84</td><td>100000 pg/mL</td><td>0.00</td></tr></table>

Mean Value spiked - Mean Value non spiked (pg/mL) % Cross-Reactivity $=$ x 100 Concentration of Cross-Reactant (pg/mL)

# Interference studies

Potential interference in the ARCHITECT Intact PTH assay from hemoglobin, bilirubin, triglycerides, and protein at the levels indicated below. Interference was demonstrated by a study based on guidance from the Clinical Laboratory Standards Institute (CLSI) Protocol EP7-A. There was no significant interference observed. Data from this study are summarized in the following table.

Potentially Interfering   

<table><tr><td>Substance</td><td>Concentration</td><td>% Mean Recovery</td></tr><tr><td>Hemoglobin</td><td>500 mg/dL</td><td>102</td></tr><tr><td>Bilirubin</td><td>20 mg/dL</td><td>98</td></tr><tr><td>Triglycerides</td><td>5000 mg/dL</td><td>105</td></tr><tr><td>Protein low</td><td>4 g/dL</td><td>106</td></tr><tr><td>Protein high</td><td>9.5 g/dL</td><td>93</td></tr><tr><td>Protein high (Routine protocol)</td><td>10.5 g/dL</td><td>94*</td></tr></table>

When using the STAT protocol, interference with high levels of protein may be observed.

# Limitations to the procedure

The applicant states Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be observed. Additional information may be required for diagnosis. The ARCHITECT Intact PTH assay has not been clinically validated for intra-operative use.

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device: The comparison studies were comprised of Serum and EDTA plasma samples.

A study was performed comparing the ARCHITECT Intact PTH assay to the predicate assay. In the study 467 specimens were analyzed with the STAT Protocol and 442 with the Routine Protocol,

In this evaluation, specimen concentrations ranged from ${ \le } 4$ to $2 0 2 7 . 2 \ \mathrm { p g / m L }$ using the STAT Protocol, from ${ \le } 3$ to $2 3 2 6 . 9 \ : \mathrm { p g / m L }$ using the Routine Protocol and from 1.2 to $1 8 1 3 . 0 \mathrm { p g / m L }$ with the predicate.

ARCHITECT Intact PTH vs. Predicate Assay Using STAT Protocol   

<table><tr><td colspan="2">Regression</td><td colspan="2"></td><td rowspan="2">Correlation Coefficient</td></tr><tr><td>Method</td><td>n</td><td>Slope</td><td>Intercept</td></tr><tr><td>Passing-Bablok</td><td>467</td><td>1.28</td><td>0.45</td><td rowspan="2">0.99</td></tr><tr><td>Least Squares</td><td>467</td><td>1.20</td><td>11.00</td></tr></table>

ARCHITECT Intact PTH vs. Predicate Assay Using Routine Protocol   

<table><tr><td colspan="2">Regression</td><td colspan="2"></td><td>Correlation Coefficient</td></tr><tr><td>Method</td><td>n</td><td>Slope</td><td>Intercept</td><td></td></tr><tr><td>Passing-Bablok</td><td>442</td><td>1.29</td><td>-0.66</td><td rowspan="2">0.99</td></tr><tr><td>Least Squares</td><td>442</td><td>1.19</td><td>11.40</td></tr></table>

200 EDTA plasma specimens were tested in singlicate using both, the STAT and the ROUTINE protocols and the predicate device. The results ranged from $5 . 5 ~ \mathrm { p g / m L }$ to $1 2 5 2 . 5 \ : \mathrm { p g / m L }$ and are presented in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Intercept Sloper</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>STAT</td><td rowspan=1 colspan=1>Passing Bablok</td><td rowspan=1 colspan=1>3.003</td><td rowspan=1 colspan=1>1.192</td><td rowspan=1 colspan=1>0.9946</td></tr><tr><td rowspan=1 colspan=1>STAT</td><td rowspan=1 colspan=1>Linear</td><td rowspan=1 colspan=1>16.898 1</td><td rowspan=1 colspan=1>1.096</td><td rowspan=1 colspan=1>1.0960.9946</td></tr><tr><td rowspan=1 colspan=1>Routine</td><td rowspan=1 colspan=1>Routine Passing Bablok</td><td rowspan=1 colspan=1>3.978</td><td rowspan=1 colspan=1>1.263</td><td rowspan=1 colspan=1>1.2630.9956</td></tr><tr><td rowspan=1 colspan=1>RoutineLinear</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>19.235 1</td><td rowspan=1 colspan=1>1.152</td><td rowspan=1 colspan=1>0.9956</td></tr></table>

b. Matrix comparison:

To evaluate the use of different anticoagulants, a study was conducted using 20 lithium heparin samples, 20 sodium heparin samples, and 20 serum samples collected in serum separator tubes (SST) and analyzed in both the stat and routine mode. The results were compared to serum samples collected in plain tube with no additives. Ten of the twenty samples were spiked with PTH to cover the assay range. The results are presented below:

For the STAT protocol:

<table><tr><td rowspan=1 colspan=3>Test Condition</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range of %differences</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=5>Normal range (24.9 pg/mL to 97.1 pg/mL)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=5 colspan=3>Serum no additiveSSTLi-HeparinSodium-Heparin</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=2>Control Condition</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-15.9 % to -6.3 %</td><td rowspan=4 colspan=1></td></tr><tr><td rowspan=2 colspan=2></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-3.6 % to 6.4 %</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-8.4% to 9.7 %</td></tr><tr><td rowspan=1 colspan=6>Upper rangee (121.7 pg/mL to 2681.1 pg/mL)</td></tr><tr><td rowspan=4 colspan=3>Serum no additiveSSTLi-HeparinSodium-Heparin</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=2>Control Condition</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-10.4 % to 6.4 %</td><td rowspan=3 colspan=1></td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-8.4 % to 3.3 %</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-8.3 % to 6.2 %</td></tr></table>

For the ROUTINE protocol:   

<table><tr><td rowspan=1 colspan=2>Test Condition</td><td rowspan=1 colspan=2>N</td><td rowspan=1 colspan=2>Range of %differences</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=7>Normal range (22.7 pg/mL to 92.6 pg/mL)</td></tr><tr><td rowspan=4 colspan=3>Serum no additiveSSTLi-HeparinSodium Heparin</td><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=2>Control Condition</td></tr><tr><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-20.5 % to -5.6 %</td><td rowspan=3 colspan=1></td></tr><tr><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-11.1% to 9.0 %</td></tr><tr><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-17.8% to 5.3 %</td></tr><tr><td rowspan=1 colspan=7>Upper range ( 120.4 pg/mL to2641.1 pg/mL)</td></tr><tr><td rowspan=3 colspan=3>Serum no additiveSSTLi-Heparin</td><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=2>Control Condition</td></tr><tr><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-10.1 % to 4.9 %</td><td rowspan=3 colspan=1></td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-7.5 % to 6.6 %</td></tr><tr><td rowspan=1 colspan=3>Sodium-Heparin</td><td rowspan=1 colspan=2>10</td><td rowspan=1 colspan=1>-7.8 % to 6.0 %</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable   
b. Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

A reference range study was conducted with USA population samples, testing a total of 168 samples from apparently healthy adults. These samples gave the values summarized in the following table.

<table><tr><td rowspan="2"></td><td colspan="7">Intact PTH (pg/mL)</td></tr><tr><td>N</td><td>Median</td><td></td><td>2.5th</td><td>percentile</td><td>97.5th</td><td>percentile</td></tr><tr><td></td><td></td><td>STAT</td><td>Routine</td><td>STAT</td><td>Routine</td><td>STAT</td><td>Routine</td></tr><tr><td>Healthy Adults</td><td>168</td><td>27.2</td><td>28.9</td><td>8.5</td><td>8.7</td><td>72.5</td><td>77.1</td></tr></table>

A reference range study was conducted with European population for the ARCHITECT Intact PTH assay to establish the reference range from apparently healthy adults. Data from this study are summarized in the following table.

<table><tr><td rowspan="2"></td><td colspan="7">Intact PTH (pg/mL)</td></tr><tr><td>N</td><td>Median</td><td></td><td>2.5th</td><td>percentile</td><td>97.5th</td><td>percentile</td></tr><tr><td></td><td></td><td>STAT</td><td>Routine</td><td>STAT</td><td>Routine</td><td>STAT</td><td>Routine</td></tr><tr><td>Healthy Adults</td><td>143</td><td>37.25</td><td>35.70</td><td>15.64</td><td>14.04</td><td>69.95</td><td>67.84</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.